Reata Pharmaceuticals, Inc.
RETA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1,379,848 | $957,794 | $4,167,166 | $6,217,576 |
| - Cash | $42,312 | $590,258 | $818,150 | $664,324 |
| + Debt | $119,464 | $136,033 | $0 | $155,017 |
| Enterprise Value | $1,457,000 | $503,569 | $3,349,016 | $5,708,269 |
| Revenue | $2,216 | $11,490 | $9,019 | $26,517 |
| % Growth | -80.7% | 27.4% | -66% | – |
| Gross Profit | $2,216 | $11,490 | $9,019 | -$97,881 |
| % Margin | 100% | 100% | 100% | -369.1% |
| EBITDA | -$269,025 | -$243,505 | -$232,324 | -$278,033 |
| % Margin | -12,140.1% | -2,119.3% | -2,575.9% | -1,048.5% |
| Net Income | -$311,901 | -$297,386 | -$247,752 | -$290,170 |
| % Margin | -14,075% | -2,588.2% | -2,747% | -1,094.3% |
| EPS Diluted | -8.59 | -8.19 | -7.35 | -9.54 |
| % Growth | -4.9% | -11.4% | 23% | – |
| Operating Cash Flow | -$204,267 | -$235,701 | -$322,340 | -$251,151 |
| Capital Expenditures | -$3,270 | -$1,329 | -$927 | -$2,673 |
| Free Cash Flow | -$207,537 | -$237,030 | -$323,267 | -$253,824 |